Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience

Journal of Clinical Oncology

Volumn 24, Issue 25, 2006, Pages 4107-4115

  Guarneri, Valentina ^a   Lenihan, Daniel J ^a   Valero, Vicente ^a   Durand, Jean Bernard ^a   Broglio, Kristine ^a   Hess, Kenneth R ^a   Michaud, Laura Boehnke ^a   Gonzalez Angulo, Ana M ^a   Hortobagyi, Gabriel N ^a   Esteva, Francisco J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CENTER; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; SYMPTOMATOLOGY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ELECTRON MICROSCOPY; ENDOCARDIUM; FEMALE; GENE EXPRESSION REGULATION; HEART; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RISK; RISK ASSESSMENT; TIME; TREATMENT OUTCOME; UNITED STATES; UPREGULATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ENDOCARDIUM; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEART; HEART FAILURE, CONGESTIVE; HUMANS; MICROSCOPY, ELECTRON; MIDDLE AGED; ODDS RATIO; RECEPTOR, ERBB-2; RISK ASSESSMENT; STROKE VOLUME; TEXAS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 33748642331     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.9551     Document Type: Article

References (32)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Paik S, Hazan R, Fisher ER, et al: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990
3. Nahta R, Esteva FJ: HER-2-targeted therapy: Lessons learned and future directions. Clin Cancer Res 9:5078-5084, 2003
4. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
5. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
6. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
7. Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808, 2002
8. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005
9. Lee KF, Simon H, Chen H, et al: Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394-398, 1995
10. Crone SA, Zhao YY, Fan L, et al: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459-465, 2002
11. von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
12. Felker GM, Thompson RE, Hare JM, et al: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077-1084, 2000
13. Hortobagyi GN, Frye D, Buzdar AU, et al: Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63:37-45, 1989
14. Mackay B, Ewer MS, Carrasco CH, et al: Assessment of anthracycline cardiomyopathy by endomyocardial biopsy. Ultrastruct Pathol 18:203-211, 1994
15. Ewer MS, Vooletich MT, Durand JB, et al: Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820-7826, 2005
16. Valero V, Gill E, Paton VE, at al: Normal cardiac biopsy results following co-administration of doxorubicin (A), cyclophosphamide (C) and trastuzumab (H) to women with HER2-positive metastatic breast cancer. J Clin Oncol 23:20s, 2004 (suppl; abstr 572)
17. Klocke FJ. Baird MG, Lorell BH, et al: ACC/ AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging: Executive summary - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation 108:1404-1418, 2003
18. Cheitlin MD, Armstrong WF, Aurigemma GP, et al: ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 16:1091-1110, 2003
19. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
20. Criteria Committee of the NYHA: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels (ed 7). Boston, MA, Little, Brown, 1973
21. Hess KR, Serachitopol DM, Brown BW: Hazard function estimators: A simulation study. Stat Med 18:3075-3088, 1999
22. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685, 2005
23. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
24. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
25. Hortobagyi GN: Trastuzumab in the treatment of breast cancer. N Engl J Med 353:1734-1736, 2005
26. Perez EA, Rodeheffer R: Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22:322-329, 2004
27. Tripathy D, Seidman A, Keefe D, et al: Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 5:293-298, 2004
28. Perez EA, Suman VJ, Davidson NE, et al: Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 22: 3700-3704, 2004
29. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005
30. Cardinale D, Sandri MT, Martinoni A, et al: Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 13:710-715, 2002
31. Snowden JA, Hill GR, Hunt P, et al: Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 26:309-313, 2000
32. Auner HW, Tinchon C, Linkesch W, et al: Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 82:218-222, 2003